Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.23
(
-0.20%
)
Bitcoin
70,109.41
(
0.30%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 209204

Tuesday, 02/13/2018 8:30:01 AM

Tuesday, February 13, 2018 8:30:01 AM

Post# of 257262
FDA approves NVS/MNTA’s 40mg Glatopa (generic Copaxone):

https://finance.yahoo.com/news/momenta-pharmaceuticals-announces-fda-approval-061500287.html

This approval was held up for one year by the manufacturing issue at PFE’s contract fill/finish plant in McPherson, KS (#msg-128816545).

Unfortunately for MNTA, MYL received FDA approval for its own (20mg and 40mg) generic Copaxone last fall, triggering considerable price erosion in the US Copaxone market. It’s now unlikely that anybody will make much money here.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now